secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001104659-24-004094
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 3.03, 5.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode CEO resigns; 1-for-40 reverse stock split effective Jan 16; cash ~$2.8M
--------------------------------------------------------------------------------

- CEO Robert Michael Dudley resigned effective Jan 13, 2024; severance of $34,607.70 and option acceleration.
- CFO Thomas A. Fitzgerald appointed interim President and CEO, effective Jan 13; retains CFO role.
- Reverse stock split at 1-for-40 ratio effective Jan 16, 2024 to regain Nasdaq minimum bid price compliance.
- Post-split shares outstanding approximately 627,448; CUSIP changes to 89357L 303; symbol remains RNAZ.
- Preliminary cash balance estimate of ~$2.8M at Dec 31, 2023, subject to year-end audit adjustment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924004094/0001104659-24-004094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924004094/tm243329d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-004094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer